文献速递头痛与眩晕

Erenumab预防慢性偏头痛的2期随机双盲安慰剂对照试验

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
PubMed 文献 · Lancet Neurol · 2017-04-28

这项2期随机双盲安慰剂对照试验纳入667例慢性偏头痛成人患者,比较皮下注射erenumab 70 mg、140 mg与安慰剂每4周一次共12周的疗效与安全性。

要点

  • Erenumab 70 mg和140 mg每4周皮下注射均显著减少慢性偏头痛患者每月偏头痛天数。
  • 两种剂量安全性良好,不良事件以注射部位疼痛、上呼吸道感染和恶心最常见。
  • 未发现抗erenumab中和抗体,生命体征、实验室及心电图无临床显著异常。

核心结论

  • 在慢性偏头痛患者中,erenumab 70 mg和140 mg可减少每月偏头痛天数,安全性特征与安慰剂相似,提示erenumab可能成为偏头痛预防的潜在疗法。

研究设计与样本

  • 2期随机双盲安慰剂对照多中心研究,纳入18-65岁慢性偏头痛成人,来自北美和欧洲69个头痛及临床研究中心。
  • 患者按3:2:2随机分配至皮下安慰剂、erenumab 70 mg或140 mg,每4周一次共12周。
  • 慢性偏头痛定义为每月头痛天数≥15天且其中偏头痛天数≥8天。
  • 主要终点为基线至双盲治疗最后4周(第9-12周)每月偏头痛天数的变化。

主要发现

  • 共667例患者随机分配:安慰剂组286例,erenumab 70 mg组191例,140 mg组190例。
  • 不良事件发生率:安慰剂组110/282例(39%),70 mg组83/190例(44%),140 mg组88/188例(47%)。
  • 严重不良事件:安慰剂组7例(2%),70 mg组6例(3%),140 mg组2例(1%),无任一组超过1例或导致停药。
  • 70 mg组11例和140 mg组3例出现抗erenumab结合抗体,均无中和抗体。

关键数值与推荐

  • 慢性偏头痛定义:每月头痛天数≥15天,其中偏头痛天数≥8天。
  • 主要疗效终点:每月偏头痛天数从基线至第9-12周的变化。
  • 随机比例3:2:2,皮下给药每4周一次,治疗12周。

临床怎么用

  • 对于慢性偏头痛成人患者,erenumab 70 mg或140 mg每4周皮下注射可作为预防性治疗选择,需关注注射部位反应和上呼吸道感染等不良事件。

局限性

  • 需进一步研究erenumab的长期疗效和安全性,以及本研究结果在真实世界中的适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The calcitonin gene-related peptide (CGRP) pathway is important in migraine pathophysiology. We assessed the efficacy and safety of erenumab, a fully human monoclonal antibody against the CGRP receptor, in patients with chronic migraine. METHODS: This was a phase 2, randomised, double-blind, placebo-controlled, multicentre study of erenumab for adults aged 18-65 years with chronic migraine, enrolled from 69 headache and clinical research centres in North America and Europe. Chronic migraine was defined as 15 or more headache days per month, of which eight or more were migraine days. Patients were randomly assigned (3:2:2) to subcutaneous placebo, erenumab 70 mg, or erenumab 140 mg, given every 4 weeks for 12 weeks. Randomisation was centrally executed using an interactive voice or web response system. Patients, study investigators, and study sponsor personnel were masked to treatment assignment. The primary endpoint was the change in monthly migraine days from baseline to the last 4 weeks of double-blind treatment (weeks 9-12). Safety endpoints were adverse events, clinical laboratory values, vital signs, and anti-erenumab antibodies. The efficacy analysis set included patients who received at least one dose of investigational product and completed at least one post-baseline monthly measurement. The safety analysis set included patients who received at least one dose of investigational product. The study is registered with ClinicalTrials.gov, number NCT02066415. FINDINGS: From April 3, 2014, to Dec 4, 2015, 667 patients were randomly assigned to receive placebo (n=286), erenumab 70 mg (n=191), or erenumab 140 mg (n=190). Erenumab 70 mg and 140 mg reduced monthly migraine days versus placebo (both doses -6·6 days vs placebo -4·2 days; difference -2·5, 95% CI -3·5 to -1·4, p<0·0001). Adverse events were reported in 110 (39%) of 282 patients, 83 (44%) of 190 patients, and 88 (47%) of 188 patients in the placebo, 70 mg, and 140 mg groups, respectively. The most frequent adverse events were injection-site pain, upper respiratory tract infection, and nausea. Serious adverse events were reported by seven (2%), six (3%), and two (1%) patients, respectively; none were reported in more than one patient in any group or led to discontinuation. 11 patients in the 70 mg group and three in the 140 mg group had anti-erenumab binding antibodies; none had anti-erenumab neutralising antibodies. No clinically significant abnormalities in vital signs, laboratory results, or electrocardiogram findings were identified. Of 667 patients randomly assigned to treatment, 637 completed treatment. Four withdrew because of adverse events, two each in the placebo and 140 mg groups. INTERPRETATION: In patients with chronic migraine, erenumab 70 mg and 140 mg reduced the number of monthly migraine days with a safety profile similar to placebo, providing evidence that erenumab could be a potential therapy for migraine prevention. Further research is needed to understand long-term efficacy and safety of erenumab, and the applicability of this study to real-world settings. FUNDING: Amgen.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017. PMID: 28460892. doi:10.1016/S1474-4422(17)30083-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。